BPC 157 therapy can recover glaucomatous rats, normalize intraocular pressure, maintain retinal integrity, recover pupil function, recover retinal ischemia, and corneal injuries (i.e., maintain transparency after complete corneal abrasion, corneal ulceration, and counteract dry eye after lacrimal gland removal or corneal insensitivity) [2,45,86,111,112,113,114]
The compounds operate through distinct, non-overlapping mechanisms (GLP-1/GIP receptor agonism versus NNMT enzyme inhibition) with no documented receptor competition or adverse pharmacokinetic interactions
Drawing BAC Water into the Syringe New sterile syringes reduce contamination during medication preparation
Each published protocol follows a standardized 14-section format that includes a quick-reference card, titration schedule, reconstitution table with worked math, side effect profile with clinical trial percentages, clinical trial results summary, compound comparison table, and 1012 answered FAQs